Justin Ferdinandus1, John Violet2, Shahneen Sandhu3,4, Michael S Hofman4,5. 1. Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany. 2. Department of Radiation Oncology. 3. Department of Medical Oncology. 4. Sir Peter MacCallum Department of Oncology. 5. Department of Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Abstract
PURPOSE OF REVIEW: Prostate-specific membrane antigen (PSMA) theranostics offers a new approach for a personalized and targeted treatment for metastatic prostate cancer. Lutetium-177-labelled PSMA-ligands (Lu-PSMA) is a radionuclide therapy that is directed to PSMA expressing prostate cancer. Clinical experience with Lu-PSMA in men with advanced prostate cancer is growing. The purpose of this review is to outline the mechanism of action of this therapy, summarize recent efficacy and toxicity data and highlight future direction and challenges in establishing Lu-PSMA treatment as part of routine clinical practice. RECENT FINDINGS: The first reports on safety and efficacy of Lu-PSMA have been retrospective series of men with advanced prostate cancer who previously failed conventional therapies and received Lu-PSMA on compassionate basis. These studies highlight promising efficacy, favourable toxicity profile and quality of life improvements. Limitation stem from the retroospective nature of these data with short follow-up. SUMMARY: Several studies suggest that radionuclide therapy with Lu-PSMA has high activity and is well tolerated. Crucial to establishing this treatment in routine clinical management will be the generation of high-level evidence from prospective trials that can confirm the encouraging patient outcomes reported to date.
PURPOSE OF REVIEW: Prostate-specific membrane antigen (PSMA) theranostics offers a new approach for a personalized and targeted treatment for metastatic prostate cancer. Lutetium-177-labelled PSMA-ligands (Lu-PSMA) is a radionuclide therapy that is directed to PSMA expressing prostate cancer. Clinical experience with Lu-PSMA in men with advanced prostate cancer is growing. The purpose of this review is to outline the mechanism of action of this therapy, summarize recent efficacy and toxicity data and highlight future direction and challenges in establishing Lu-PSMA treatment as part of routine clinical practice. RECENT FINDINGS: The first reports on safety and efficacy of Lu-PSMA have been retrospective series of men with advanced prostate cancer who previously failed conventional therapies and received Lu-PSMA on compassionate basis. These studies highlight promising efficacy, favourable toxicity profile and quality of life improvements. Limitation stem from the retroospective nature of these data with short follow-up. SUMMARY: Several studies suggest that radionuclide therapy with Lu-PSMA has high activity and is well tolerated. Crucial to establishing this treatment in routine clinical management will be the generation of high-level evidence from prospective trials that can confirm the encouraging patient outcomes reported to date.
Authors: Heather D Agnew; Matthew B Coppock; Matthew N Idso; Bert T Lai; JingXin Liang; Amy M McCarthy-Torrens; Carmen M Warren; James R Heath Journal: Chem Rev Date: 2019-03-06 Impact factor: 60.622
Authors: Manuel Scimeca; Nicoletta Urbano; Rita Bonfiglio; Sarah Natalia Mapelli; Carlo Vittorio Catapano; Giuseppina Maria Carbone; Sara Ciuffa; Mario Tavolozza; Orazio Schillaci; Alessandro Mauriello; Elena Bonanno Journal: Contrast Media Mol Imaging Date: 2018-12-09 Impact factor: 3.161
Authors: Matthew Dowling; Jonathan Samuelson; Bahaa Fadl-Alla; Holly C Pondenis; Mark Byrum; Anne M Barger; Timothy M Fan Journal: PLoS One Date: 2019-01-02 Impact factor: 3.240